Part 2 of Cytel’s Webinar on Considerations for SCAs in Clinical Trials Now Available

A new webinar offered by Cytel details important considerations for researchers seeking to create synthetic control arms (SCAs) using real world data (RWD). Although SCAs are typically considered to be a fast-track method of getting a drug to market, this is an incorrect assumption. SCAs can require extensive time and resources to be useful. The webinar details solutions to common challenges associated with SCAs and RWD selection.

“Critical elements of SCA construction occur long before a single data point is analyzed. Statisticians must apply their insight to choose vendors, engage literature reviews, and coordinate stakeholders from clinical, statistical and market-access. Getting these groups together can take a surprising amount of time. Another factor that needs significant consideration is which data source to use, especially when you are fortunate enough to have more than one option available.” Read more here.

(Source: Mansha Sachdev, Cytel, 6/17/21)